Results: A total of 149 nurses participated in this survey (France, n = 30; Germany, n = 40; Italy, n = 30; Spain, n = 19; UK, n = 30). 'Easy to operate the self-injection' was ranked as the most important attribute (mean score of 6.8), followed by 'easy to grip' (6.6) and 'intuitive/self-explaining usage' (6.6 pharmacokinetic endpoints were comparable, as was the incidence of treatment-emergent adverse events [8] .
Treatments for RA, such as the Enbrel and Benepali, are administered by subcutaneous (SC) injection [6, 9] . This route of administration is not uncommon, particularly in chronic diseases, such as RA, diabetes, and multiple sclerosis [10] [11] [12] . A number of different devices are available for SC injection (prefilled syringes and autoinjector devices), with selection of device being influenced by a number of factors, including physician and patient preference [13] . Patients receiving this type of medication need to know how to self-administer their medication, with training typically being provided by nurses [14] [15] [16] .
Several studies have shown that patients prefer autoinjector devices over more conventional methods of treatment administration (e.g., vial and syringe, prefilled syringe), based on factors, such as ease of use, convenience, acceptability, and satisfaction [10, [17] [18] [19] [20] . Moreover, some patients have reported improved quality of life when using autoinjectors [19] . This preference for autoinjectors has been observed not only in patients with RA [10, 18, 20] , but also in patients with chronic conditions, such as type 2 diabetes [19] and anemia [17] . Results from a two-phase, cross-sectional study in patients with RA, psoriatic arthritis, and ankylosing spondylitis, which assessed patient's acceptance of switching adalimumab from a prefilled syringe to an autoinjector device, reported increased treatment adherence and self-administration, and decreased pain at the injection site following this switch. Furthermore, 86.3% of patients rated the autoinjector as easier to use than the prefilled syringe, with 96.1% selecting the autoinjector as their preferred delivery system [20] . 
Participant Recruitment and Eligibility
Kantar Health GmbH outsourced recruitment to another agency, Schmiedl Marktforschung GmbH, who enrolled nurses from various sources, including nurse databases, office-based practices, and through recommendations from hospitals and other nurses. To be eligible to participate in the survey, nurses had to have recent experience in using the Enbrel MYCLIC autoinjector (a minimum of twice in the previous/last month; on average, eight times in the last month) in their patients with RA. Nurses provided written consent before participating in the study and were compensated for their time with an honorarium.
Questionnaire Design
An English master questionnaire was created, tested, and validated in pilot interviews to ensure appropriate flow and content. The questionnaire was translated into German, Italian, French, and Spanish. Interviews were conducted in the local language of the European country.
Each nurse participated in a 25-min face-to-face interview, during which the interviewer read out questions from the set questionnaire and noted the responses.
Questions were sequential and broadly divided into sections based on the types of information sought. In addition, during the allocated 25 min, nurses were shown an instructional video and device-handling leaflet, received a live demonstration on the Benepali autoinjector and had access to both the Benepali and Enbrel MYCLIC autoinjectors (see supplementary material for full details on the questionnaire).
In the first section of the questionnaire (Q1),
nurses were asked to rate the importance of ten attributes, when considering an autoinjector device in general, on a scale of 1-7 (1 = not important at all; 7 = extremely important). The attributes that were assessed at random during the interviews were: (1) size of the autoinjector,
(2) attractive design of the autoinjector, (3) easy to grip the autoinjector, (4) easy to operate the self-injection with the autoinjector, (5) audible feedback after treatment has been successfully injected, (6) visual feedback after treatment has been successfully injected, (7) concealing the injection needle in the injector body, (8) intuitive/self-explaining usage, (9) button-free autoinjector, and (10) 
Importance of Attributes When Using an Autoinjector Device
Nurses were asked to evaluate the importance of ten attributes, when considering an autoinjector device in general, on a scale of 1-7 (1 = not important at all; 7 = extremely important). Overall, 'easy to operate the self-injection' was ranked as the most important attribute by nurses (mean score of 6.8), followed by 'easy to grip' (6.6), 'intuitive/self-explaining usage' (6.6), 'concealing the injection needle in the injector body' (6.4), 'audible feedback after treatment has been successfully injected' (6.2), and 'visual feedback after treatment has been successfully injected' (6.2). The attributes of 'weight of the autoinjector,' 'size of the autoinjector,' and 'button-free device' were considered to be less important attributes by nurses, with mean scores of 5.8, 5.6, and 5.6, respectively. 'Attractive design of the autoinjector' was considered to be the least important attribute by nurses, with a mean score of 3.9 (Fig. 1 ).
Nurse Preferences for Autoinjector Based on Attributes
Nurses were asked for their preference of autoinjector based on nine of the ten attributes previously assessed ('button-free device' was not included in this section). Overall, attributes of 'easier to operate' and 'more intuitive to use' were strong differentiators for the Benepali autoinjector compared with the Enbrel MYCLIC autoinjector; 87% and 68% of nurses reported that the Benepali autoinjector was 'easier to operate' and 'more intuitive to use' than the Enbrel MYCLIC autoinjector (Fig. 2 ). In addition, country-specific data showed that nurses from all five EU countries preferred the Benepali autoinjector compared with the Enbrel MYCLIC autoinjector based on these two attributes (Fig. 3a, b) .
Overall, nurses preferred the Benepali autoinjector, compared with the Enbrel MYCLIC autoinjector, for attributes of 'right weight,' 'better audible feedback,' 'better visual feedback,' 'easier to grip,' 'better size,' and 'attractive design' (Fig. 2) . The attribute of 'conceals the injection needle better' was rated as being the same for both autoinjectors by 69% of nurses.
Nurse Opinions on Patient Preference for Autoinjector and Attributes that Drive

Nurse Choice of Autoinjector
Nurses were asked their opinion, as to which autoinjector their patients with RA would prefer to use for self-injection. The majority of nurses [n = 128/149 (86%)] reported that their patients would prefer the Benepali autoinjector; only a very small number of nurses [n = 9/149 (6%)] reported that their patients would prefer the Enbrel MYCLIC autoinjector. Twelve nurses (8%) stated that their patients would have no preference for either device. These findings were replicated across the five EU countries (Fig. 4 ).
Nurses were also asked to select the top three attributes that drove their preference for one autoinjector over the other. Among the 128 nurses who indicated a preference for the Benepali autoinjector, the reasons most commonly given for their preference were ''easy to operate'' (n = 96) followed by ''button-free autoinjector'' (n = 84). Among the nine nurses who indicated a preference for the Benepali autoinjector, the most common reasons given were ''easy to operate'' (n = 6), followed by ''easy to grip'' (n = 5), ''audible feedback'' (n = 4), and ''concealing the injection needle'' (n = 4) ( Fig. 5 ). Attributes of 'easy to operate the self-injection' and 'button-free autoinjector' were also reported as key drivers impacting nurses' choice of autoinjector. Taken together, these attributes may be collectively described as those that may allow easy handling of the autoinjector by patients with RA, suggesting that nurses in Europe consider the Benepali autoinjector to be easier to handle than the Enbrel MYCLIC autoinjector. This is of key importance, as the RA patient population presents specific challenges for the accurate administration of SC therapies due to common symptoms of joint pain and limited manual dexterity [22] . 
DISCUSSION
